
Pfizer CEO Albert Bourla has ‘predicted’ that life will return to ‘normal’ around springtime.
In an interview published by the French news outlet Le Figaro, Bourla also said that even though he expects covid to continue circulating for many years, he doen’t think there will be a need for major restrictions during future waves.

BYPASS THE CENSORS
Sign up to get unfiltered news delivered straight to your inbox.
You can unsubscribe any time. By subscribing you agree to our Terms of Use
The Epoch Times reports: The Pfizer chief credited developments in COVID-19 testing, vaccines, and therapeutics for his optimistic outlook, telling BFM TV in a separate interview that he expects the current Omicron-driven wave to be the “last with so many restrictions.”
Latest Videos
Pentagon: ‘UFO’s Are Real, You Will See More of Them’ – Stunning Admission
Democrats Say Men Can Now Get Abortions Too
Rothschild Slams Elon Musk For Saying He Won’t Vote Democrat Anymore
Freudian Slip! George W. Bush Slams the ‘Unjustified Invasion of Iraq’
Pedophile ‘Code Words’ Found in Hunter Biden’s Leaked Emails
Buffalo Killer’s Goal Was To ‘Remove Gun Rights’ in US
Bill Gates Orders Adults Over 50 To Get ‘Ongoing’ Covid Boosters ‘Every 6 Months’
Hunter Biden Emails Reveal He Fathered Child With ANOTHER Prostitute, Left Her Addicted to Narcotics
Lindsey Graham Caught on Tape Saying Joe Biden Is ‘Best President’
At the same time, Bourla predicted that COVID-19 would continue to circulate for many years to come.
“This is a virus that has spread all over the world so it is very difficult to get rid of,” Bourla told BFM TV.
Bourla also said Pfizer was planning to invest over half a billion dollars in France over the next five years to boost global production of its COVID-19 pill Paxlovid, which obtained emergency approval in the United States in December.
The investment will pertain to the production of active pharmaceutical ingredient (API) for Paxlovid at a plant run by French pharmaceutical group Novasep, which announced on Jan. 17 it had signed a letter of intent with Pfizer to bolster the drugmaker’s global supply chain of the pill.
“We are honored by this renewed proof of confidence, Pfizer being a long-time customer of Novasep and we are of course proud to contribute to the manufacturing of this medicine which has shown in clinical trials to have a positive impact on hospitalization among at-risk COVID-19 patients,” Novasep CEO Dr. Michel Spagnol said in a statement.